DOCSLIB.ORG

Pain Management at the End of Life

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pain Management at the End of Life Position Statement American Society for Pain Management Nursing and Hospice and Palliative Nurses Association Position Statement: Pain Management at the End of Life - - - Patrick Coyne, MSN, RN,* Carol Mulvenon, APRN, ACHPN,† and Judith A. Paice, PhD, RN‡ - ABSTRACT: Pain at the end of life continues to be of great concern as it may be unrecognized or untreated. Although nurses have an ethical obligation to reduce suffering, barriers remain regarding appropriate and adequate pain management at the end of life. This joint position From the *Medical University of statement from the American Society for Pain Management Nursing South Carolina, Charleston, South and Hospice and Palliative Nurses Association contains recommen- Carolina; †University of Kansas Health System, Kansas City, Kansas; dations for nurses, prescribers, and institutions that would improve ‡Cancer Pain Program, Division pain management for this vulnerable population. Hematology-Oncology, Feinberg Ó 2017 by the American Society for Pain Management Nursing School of Medicine Chicago, Northwestern University, Chicago, Illinois. The American Society for Pain Management Nursing (ASPMN) and Hospice and Palliative Nurses Association (HPNA) hold the position that nurses and other Address correspondence to Judith A. Paice, PhD, RN, Cancer Pain Program, health care providers must advocate for effective, efficient, and safe pain and Division Hematology-Oncology, 676 symptom management to alleviate suffering for every patient receiving end-of- North St. Clair Street, Suite 850, life care regardless of their age, diseases, history of substance misuse, or site Chicago, IL 60611. E-mail: j-paice@ of care. This position statement is directed to the special needs of those individ- northwestern.edu uals with a serious illness and a prognosis of days to months. Other guidelines are Received October 14, 2017; available to direct care for those receiving active treatment or those who are Accepted October 29, 2017. long-term survivors (Chou et al., 2009; Dowell, Haegerich, & Chou, 2016; Paice et al., 2016; Ripamonti, Santini, Maranzano, Berti, & Roila, 2012; Swarm 1524-9042/$36.00 et al., 2013). In addition to the recommendations provided in this position Ó 2017 by the American Society for statement, the authors endorse early care integration with interdisciplinary Pain Management Nursing https://doi.org/10.1016/ palliative care teams and referral to hospice when appropriate (Ferrell et al., j.pmn.2017.10.019 2017). Pain Management Nursing, Vol 19, No 1 (February), 2018: pp 3-7 4 Coyne, Mulvenon, and Paice BACKGROUND than accelerate death (Sutradhar et al., 2014). A review of five studies found there is no evidence that initiation of The prevalence of pain toward the end of life remains treatment or increases in dose of opioids or sedatives is unacceptably high. In a recent study of elderly nursing associated with precipitation of death (Sykes & Thorns, home residents enrolled in hospice, the prevalence of 2003). A retrospective study of patients cared for at pain was close to 60% (Hunnicutt, Tjia, & Lapane, home found that the use of opioids, even high-dose opi- 2017). A meta-analysis of 52 studies spanning 40 years oids or escalating doses, did not shorten survival found that 64% of patients with advanced cancer have (Bengoechea, Gutierrez, Vrotsou, Onaindia, & Lopez, pain. One-third of all patients in the reviewed studies 2010). Despite this evidence to the contrary, nurses rated their pain as moderate or severe (van den continue to identify the use of opioids in managing symp- Beuken-van Everdingen et al., 2007b). In individuals toms as one of the ethical dilemmas they face (Cheon, for whom curative or palliative chemotherapy was Coyle, Wiegand, & Welsh, 2015). In a study to explore no longer feasible, the prevalence of cancer pain the perceptions of nurses regarding medication use at increased to 75% (van den Beuken-van Everdingen the end-of-life, they reported hastening death and the po- et al., 2007a). In a systematic review of the prevalence tential to decrease respirations as their primary fears of symptoms at the end of life, the overall prevalence (Howes, 2015). of pain was identified as 52.4% (Kehl & Kowalkowski, 2013). A consecutive cohort study to describe both in- Nurses have an ethical responsibility to provide clini- tensity and prevalence of symptoms in 18,975 pa- cally excellent care to address a patient’s pain. Clinically excellent pain management considers clinical indications, tients imminently dying in either a palliative care mutual identification of goals for pain management, inter- unit (70%), in an acute hospital with palliative care professional collaboration, and awareness of professional support (8.7%), or at home (8.7%) found that although standards for the assessment and management of different more than half of the patients were not experiencing types of pain.’’ (ANA Position Statement The Ethical Re- distressing symptoms, of those patients who did have sponsibility to Manage Pain and Suffering—Draft State- symptoms, 22.2% identified pain as problematic, and ment) (American Nurses Association, 2017) 4.2% reported severe pain (Clark et al., 2016). Therefore, nurses must use evidence-based, effec- To examine the definition of a good death that in- tive doses of medications prescribed for symptom con- cludes perspectives from patients, family members, trol, and nurses must advocate on behalf of the patient and health care providers, a literature review of pub- when prescribed medication is not managing pain and lished studies revealed that an essential core of a other distressing symptoms. Additionally, nurses must good death as identified by 81% of respondents was advocate for nonpharmacologic therapies, including ‘‘pain-free status’’ (Meier et al., 2016) Similarly, recent psychological approaches, physical measures, integra- systematic reviews were conducted with the aim of tive therapies, and interventional techniques, when determining the most important elements of end of appropriate. life care identified by patients and their families dying To provide clinically excellent care, nurses must in the hospital. Expert care, which includes manage- be aware of the barriers to assessment and treatment ment of pain and other symptoms, was identified as of pain. Undertreatment of pain is more common in in- one of the essential end-of-life care domains (Virdun, dividuals who are not able to speak for themselves, Luckett, Davidson, & Phillips, 2015; Virdun, Luckett, particularly infants and children, and those who are Lorenz, Davidson, & Phillips, 2017). developmentally or cognitively impaired (Herr, In most cases, the array of symptoms and existen- Coyne, McCaffery, Manworren, & Merkel, 2011). Other tial distress felt by patients with advanced disease can groups at risk for undertreatment include the elderly, be prevented or relieved through optimal care. Howev- those with a history of substance use disorder, those er, in a study employing interviews with a bereaved with limited social and economic resources, and those family member or friend of the decedent, these loved who speak a language different from that of their ones reported that the patient experienced unmet health care professional (Greco et al., 2014; Oliver need for pain management during the end-of-life et al., 2012; Paice & Von Roenn, 2014). period (25.2%) (Teno, Freedman, Kasper, Gozalo, & Mor, 2015). This finding and many other studies rein- BARRIERS TO CARE force the ongoing need to improve the management of pain for people at the end of life (Ziegler, Mulvey, Barriers to optimal pain management at the end of life Blenkinsopp, Petty, & Bennett, 2016). come in many forms (Kwon, 2014; White, Coyne, & Effective pain and symptom management at the end White, 2012). The presence of these barriers has of life increases quality of life and may prolong life rather been associated with less effective pain control End-of-Life Pain Management 5 (Gunnarsdottir et al., 2017; Mayahara, Foreman, Wilbur, Palliative Care Paice, & Fogg, 2015). Although divided into three major Palliative care means patient and family-centered care that categories, the items are not exclusive to just one group: optimizes qualityof life by anticipating, preventing, and treat- ing suffering. Palliative care throughout the continuum of Patient and Family illness involves addressing the physical, intellectual, emotional, social, and spiritual needs and to facilitate patient Denial by the patient and/or family, causally linking pain autonomy, access to information, and choice (National as a sign of deterioration Consensus Project for Quality Palliative Care, 2013). Fear that increasing pain is a herald of disease progression Patients’ and families’ belief that pain is a natural part of illness and cannot be relieved ETHICAL CONSIDERATIONS Stoicism Cognitive and affective factors Nurses have an ethical responsibility to relieve pain Fear of addiction and abuse and suffering (American Nurses Association, May 9, 2017). Nurses caring for patients at the end of life should recognize that the provision of medications to Health Care Providers relieve suffering is consistent with accepted ethical Inadequate assessment of pain, including denial of its and legal principles. Additionally, there must be recog- presence and not utilizing an assessment scale designed nition that the risk of hastening death by the adminis- for the special needs of each patient when indicated tration of opioids to patients with serious illnesses is Lack of
Load more

Recommended publications
  • Update on the Management of Pain, Agitation, and Delirium in the ICU
    Update on the Management of Pain, Agitation, and Delirium in the ICU Kevin E. Anger, Pharm.D., BCPS Gilles Fraser, Pharm.D., MCCM Paul M. Szumita, Pharm.D., BCCCP, Manager Investigational Drug Clinical Pharmacist in Critical BCPS, FCCM Service Brigham and Women’s Care Clinical Pharmacy Practice Manager Hospital Maine Medical Center Brigham and Women’s Hospital Boston, Massachusetts Portland, Maine Boston, Massachusetts Disclosures • Faculty have nothing to disclose. Objectives • Describe recent literature on management of pain, agitation, and delirium (PAD) in the intensive care unit (ICU). • Apply key concepts in the selection of sedatives, analgesics, and antipsychotic agents in critically ill patients. • Recommend methods to overcome key barriers to optimizing pain, sedation, and delirium pharmacotherapy in critically ill patients. Case-Based Approach to Pain Management in the ICU Kevin E. Anger, Pharm.D., BCPS Manager Investigational Drug Service Brigham and Women’s Hospital Boston, Massachusetts Time for a Poll How to vote via the web or text messaging From any browser From a text message Pollev.com/ashp 22333 152964 How to vote via text message How to vote via the web Question #1 DT is a 70 yo male w/ COPD, S/P XRT for NSC lung CA, now admitted to the medical ICU for respiratory failure secondary to pneumonia meeting ARDS criteria. Significant home medications include oxycodone sustained release 40mg TID, oxycodone 10- 20mg Q4hrs PRN pain, Advair 500/50mcg BID, ASA 81mg QD, and albuterol neb Q4hrs PRN. DT is intubated is currently
    [Show full text]
  • Pharmacists' Roles on the Pain Management Team, Fall 2014
    Fall 2014, Volume 8, Issue 2 Canadian Pharmacy > Research > Health Policy > Practice > Better Health Pharmacists’ Roles on the Pain Management Team harmacists are an important resource for managing pain in their patients, in order to both optimize treatment and Pprevent the unintended consequences of potent analgesics. While the role of pharmacists in pain management was first addressed inthe Translator Summer 2012 edition1, this rapidly evolving area of pharmacy practice has generated a number of innovative models that highlight the unique role of the pharmacist. As Canadian pharmacists embrace expanded scopes of practice, there is an opportunity to specifically leverage their services to assist patients in managing their pain. This issue of the Translator highlights four different approaches to enhanced involvement of pharmacists in the management of chronic pain: n Pharmacist-led management of chronic pain: a randomized controlled exploratory trial from the UK n A pharmacist-initiated intervention trial in osteoarthritis n A pharmacist-led pain consultation for patients with concomitant substance use disorders n The impact of pharmacists in translating evidence to patients with low back pain 1 The Translator, Summer 2012, 6:3 Pharmacist-led management of chronic pain in primary care: results from a randomized controlled exploratory trial Bruhn H, Bond CM, Elliott AM, et al. Pharmacist-led management of chronic pain in primary care; results from a randomized controlled exploratory trial. BMJ Open 2013;3:e002361. Issue: In the UK, an estimated 80% of medication review of each patient’s medical chronic pain sufferers still report pain after Pharmacist prescribing and records, followed by a face-to-face consul- four years of follow-up.1 Most patients refer reviewing pain medication may tation.
    [Show full text]
  • Pain Management in People Who Have OUD; Acute Vs. Chronic Pain
    Pain Management in People Who Have OUD; Acute vs. Chronic Pain Developer: Stephen A. Wyatt, DO Medical Director, Addiction Medicine Carolinas HealthCare System Reviewer/Editor: Miriam Komaromy, MD, The ECHO Institute™ This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under contract number HHSH250201600015C. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government. Disclosures Stephen Wyatt has nothing to disclose Objectives • Understand the complexities of treating acute and chronic pain in patients with opioid use disorder (OUD). • Understand the various approaches to treating the OUD patient on an agonist medication for acute or chronic pain. • Understand how acute and chronic pain can be treated when the OUD patient is on an antagonist medication. Speaker Notes: The general Outline of the module is to first address the difficulties surrounding treating pain in the opioid dependent patient. Then to address the ways that patients with pain can be approached on either an agonist of antagonist opioid use disorder treatment. Pain and Substance Use Disorder • Potential for mutual mistrust: – Provider • drug seeking • dependency/intolerance • fear – Patient • lack of empathy • avoidance • fear Speaker Notes: It is the provider that needs to be well educated and skillful in working with this population. Through a better understanding of opioid use disorders as a disease, the prejudice surrounding the encounter with the patient may be reduced.
    [Show full text]
  • Perioperative Pain Management for the Chronic Pain Patient with Long-Term Opioid Use
    1.5 ANCC Contact Hours Perioperative Pain Management for the Chronic Pain Patient With Long-Term Opioid Use Carina Jackman In the United States nearly one in four patients present- patterns of preoperative opioid use. Approximately one ing for surgery reports current opioid use. Many of these in four patients undergoing surgery in the study re- patients suffer from chronic pain disorders and opioid ported preoperative opioid use (23.1% of the 34,186-pa- tolerance or dependence. Opioid tolerance and preexisting tient study population). Opioid use was most common chronic pain disorders present unique challenges in regard in patients undergoing orthopaedic spinal surgery to postoperative pain management. These patients benefi t (65%). This was followed by neurosurgical spinal sur- geries (55.1%). Hydrocodone bitartrate was the most from providers who are not only familiar with multimodal prevalent medication. Tramadol and oxycodone hydro- pain management and skilled in the assessment of acute pain, chloride were also common ( Hilliard et al., 2018 ). but also empathetic to their specifi c struggles. Chronic pain Given this signifi cant population of surgical patients patients often face stigmas surrounding their opioid use, with established opioid use, it is imperative for both and this may lead to underestimation and undertreatment nurses and all other providers to gain an understanding of their pain. This article aims to review the challenges of the complex challenges chronic pain patients intro- presented by these complex patients and provide strate- duce to the postoperative setting. gies for treating acute postoperative pain in opioid-tolerant patients. Defi nitions Common pain terminology as defined by the Chronic Pain and Long-Term International Association for the Study of Pain, a joint Opioid Use consensus statement by the American Society of Addiction Medicine, the American Academy of Pain The burden of chronic pain in the United States is stag- Medicine and the American Pain Society (2001 ), and the gering.
    [Show full text]
  • Menu of Pain Management Clinic Regulation
    Menu of Pain Management Clinic Regulation The United States is in the midst of an unprecedented epidemic of prescription drug overdose deaths.1 More than 38,000 people died of drug overdoses in 2010, and most of these deaths (22,134) were caused by overdoses involving prescription drugs.2 Three-quarters of prescription drug overdose deaths in 2010 (16,651) involved a prescription opioid pain reliever (OPR), which is a drug derived from the opium poppy or synthetic versions of it such as oxycodone, hydrocodone, or methadone.3 The prescription drug overdose epidemic has not affected all states equally, and overdose death rates vary widely between states. States have the primary responsibility to regulate and enforce prescription drug practice. Although state laws are commonly used to prevent injuries and their benefits have been demonstrated for a variety of injury types,4 there is little information on the effectiveness of state statutes and regulations designed to prevent prescription drug abuse and diversion. This menu is a first step in assessing pain management clinic laws by creating an inventory of state legal strategies in this domain. Introduction One type of law aimed at preventing inappropriate prescribing is regulation of pain management clinics, often called “pill mills” when they are sources of large quantities of prescriptions. Pill mills have become an increasing problem in the prescription drug epidemic, and laws have been enacted to prevent these facilities from prescribing controlled substances inappropriately. A law was included in this resource as a pain management clinic regulation if it requires state oversight and contains other requirements concerning ownership and operation of pain management clinics, facilities, or practice locations.
    [Show full text]
  • Palliative Care Symptom Guide
    July 2019 UPMC PALLIATIVE AND SUPPORTIVE INSTITUTE Palliative Care Symptom Guide Table of Contents: Pain Management ……………………………………………………………………………………………………………………….. Assessment …………………………………………………………………………………………………………………………… 1 Adjuvant and Non-Opioid Agents for Pain ……………………………………………………………………………………….... 2 Principles of Opioid Therapy ……………………………………………………………………………………………….….…. 3-4 Select Opioid Products ……………………………………………………………………………………………………………… 5 Opioid Equianalgesic Equivalencies ………………………………………………………………………...…………………..… 6 Patient Controlled Analgesia (PCA) ……………………………………………………………………………………………….. 7 Opioid Induced Constipation ……………………………………………………………………………………………………… 8-9 Prescribing Outpatient Naloxone ………………………………………………………………………………………………… 10 Interventional Pain Management …………………………………………………………………………………………………. 11 Medical Cannabinoids ……………………………………………………………………………………………………………… 12 Dyspnea ………………………………………………………………………………………………………………………………… Assessment ………………………………………………………………………………………………………………………… 13 Treatment …………………………………………………………………………………………………………………………… 14 Nausea and Vomiting Treatment ……………………………………………………………………………………………..……… 15 Delirium …………………………………………………………………………………………………………………………………. 16 Diagnostic Criteria ……………………………………………………………………………….……………………….………... 17 Treatment ………………………………………………………………………………..…………………………………………. 18 Depression and Anxiety Treatment ……………………………………………………..…………..…………………………….…. 19 Oral Secretions ……………………………………………………..…………………………………………………………………. 20 Spirituality Pearls ……………………………………………………..………………………………………………………………. 21 Palliative
    [Show full text]
  • Veterinary Anesthesia and Pain Management Secrets / Edited by Stephen A
    Publisher: HANLEY & BELFUS, INC. Medical Publishers 210 South 13th Street Philadelphia, PA 19107 (215) 546-7293; 800-962-1892 FAX (215) 790-9330 Web site: http://www.hanleyandbelfus.com Note to the reader Although the information in this book has been carefully reviewed for cor­ rectness of dosage and indications, neither the authors nor the editor nor the publisher can accept any legal responsibility for any errors or omissions that may be made. Neither the publisher nor the editor makes any warranty, expressed or implied, with respect to the material contained herein. Before prescribing any drug. the reader must review the manu­ facturer's correct product information (package inserts) for accepted indications, absolute dosage recommendations. and other information pertinent to the safe and effective use of the product described. This is especially important when drugs are given in combination or as an adjunct to other forms of therapy Library of Congress Cataloging-in-Publication Data Veterinary anesthesia and pain management secrets / edited by Stephen A. Greene. p. em. - (The Secrets Series®) Includes bibliographical references (p.). ISBN 1-56053-442-7 (alk paper) I. Veterinary anesthesia-Examinations, questions. etc. 2. Pain in animals­ Treatment-Examinations, questions, etc. I. Greene, Stephen A., 1956-11. Series. SF914.V48 2002 636 089' 796'076--dc2 I 2001039966 VETERINARY ANESTHESIA AND PAIN MANAGEMENT SECRETS ISBN 1-56053-442-7 © 2002 by Hanley & Belfus, Inc. All rights reserved. No part of this book may be repro­ duced, reused, republished. or transmitted in any form, or stored in a database or retrieval system, without written permission of the publisher Last digit is the print number: 9 8 7 6 5 4 3 2 CONTRIBUTORS G.
    [Show full text]
  • Pain Management & Palliative Care
    Guidelines on Pain Management & Palliative Care A. Paez Borda (chair), F. Charnay-Sonnek, V. Fonteyne, E.G. Papaioannou © European Association of Urology 2013 TABLE OF CONTENTS PAGE 1. INTRODUCTION 6 1.1 The Guideline 6 1.2 Methodology 6 1.3 Publication history 6 1.4 Acknowledgements 6 1.5 Level of evidence and grade of guideline recommendations* 6 1.6 References 7 2. BACKGROUND 7 2.1 Definition of pain 7 2.2 Pain evaluation and measurement 7 2.2.1 Pain evaluation 7 2.2.2 Assessing pain intensity and quality of life (QoL) 8 2.3 References 9 3. CANCER PAIN MANAGEMENT (GENERAL) 10 3.1 Classification of cancer pain 10 3.2 General principles of cancer pain management 10 3.3 Non-pharmacological therapies 11 3.3.1 Surgery 11 3.3.2 Radionuclides 11 3.3.2.1 Clinical background 11 3.3.2.2 Radiopharmaceuticals 11 3.3.3 Radiotherapy for metastatic bone pain 13 3.3.3.1 Clinical background 13 3.3.3.2 Radiotherapy scheme 13 3.3.3.3 Spinal cord compression 13 3.3.3.4 Pathological fractures 14 3.3.3.5 Side effects 14 3.3.4 Psychological and adjunctive therapy 14 3.3.4.1 Psychological therapies 14 3.3.4.2 Adjunctive therapy 14 3.4 Pharmacotherapy 15 3.4.1 Chemotherapy 15 3.4.2 Bisphosphonates 15 3.4.2.1 Mechanisms of action 15 3.4.2.2 Effects and side effects 15 3.4.3 Denosumab 16 3.4.4 Systemic analgesic pharmacotherapy - the analgesic ladder 16 3.4.4.1 Non-opioid analgesics 17 3.4.4.2 Opioid analgesics 17 3.4.5 Treatment of neuropathic pain 21 3.4.5.1 Antidepressants 21 3.4.5.2 Anticonvulsant medication 21 3.4.5.3 Local analgesics 22 3.4.5.4 NMDA receptor antagonists 22 3.4.5.5 Other drug treatments 23 3.4.5.6 Invasive analgesic techniques 23 3.4.6 Breakthrough cancer pain 24 3.5 Quality of life (QoL) 25 3.6 Conclusions 26 3.7 References 26 4.
    [Show full text]
  • Managing Pain Anywhere
    Managing Pain – Anywhere! The Role of the Pharmacist Lee Kral, PharmD, BCPS The University of Iowa Center for Pain Medicine November 2012 Outline 1. Patient care settings 2. Barriers to pharmacist involvement 3. Establishing a practice 4. Qualifications, resources 5. Benefits/outcomes Where is the Pain? Outpatient clinics ER Hospital OR/PACU Inpatient units Discharge Do YOU do pain management in your practice? YES NO Pharmacist involvement in pain management Practice sites Hospital settings Emergency Department – acute pain 21% Outpatient clinics – chronic pain 45% 12% Inpatient units – acute and/or chronic pain 22% Critical care Palliative Care Community hospitals Oncology Federal hospitals Surgery Hospice Adult Medicine Other OR/PACU – acute pain Where do PPC pharmacists come from? Providers perceive need Pharmacy department initiative Sentinel events, safety issues Drug diversion/enforcement concerns Joint Commission mandates Gradual practice transition (fam med, hem-onc) Pain management practice model shift Which of the following is something that a PPC pharmacist might do? a. Prescribe opioids b. Order urine toxicology c. Obtain medication histories d. Write orders for post-op pain in the PACU e. All of the above What are the barriers? Pharmacist lack of knowledge, expertise Budgetary constraints Resistance from medical staff Providers unfamiliar with qualifications Ignorance of nursing, medical, pharmacy staff Unclear role of the pharmacist Previously established methods Lack of mentorship What are the qualifications? PGY-2 Pain and Palliative Care residency Certified Pain Educator (ASPE) ASHP PPC traineeship American Academy of Pain Management Certificate programs Experience and interest Juba KM. J Pharmacy Practice 2012; 00(0):1-4 What are the outcomes? Clinic setting1 Generated > $100,000 annual true revenue Saved health plans > $455,000 annually Reduce pain scores Managed maintenance monitoring Opioid refill clinic2 Reduced drug costs Reduced utilization of health care services Provider satisfaction Improved patient behavior 1.
    [Show full text]
  • Post- Operative Pain- Relief
    PPoosstt-- OOppeerraattiivvee PPaaiinn-- RReelliieeff • Pain is often the patient’s presenting symptom. It can provide useful clinical information and it is your responsibility to use this information to help the patient and alleviate suffering. • Manage pain wherever you see patients (emergency, operating room and on the ward) and anticipate their needs for pain management after surgery and discharge. • Do not unnecessarily delay the treatment of pain; for example, do not transport a patient without analgesia simply so that the next practitioner can appreciate how much pain the person is experiencing. • Pain management is our job. Pain Management and Techniques • Effective analgesia is an essential part of postoperative management. • Important injectable drugs for pain are the opiate analgesics. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as diclofenac (1 mg/kg) and ibuprofen can also be given orally and rectally, as can paracetamol (15 mg/kg). • There are three situations where an opiate might be given: pre- operatively, intra-operatively, post-operatively. •• Opiate premedication is rarely indicated, although an injured patient in pain may have been given an opiate before coming to the operating room. • Opiates given pre- or intraoperatively have important effects in the postoperative period since there may be delayed recovery and respiratory depression, even necessitating mechanical ventilation. (continued to next page) PPoosstt-- OOppeerraattiivvee PPaaiinn-- RReelliieeff ((ccoonnttiiinnuueedd)) • Short acting opiate fentanyl is used intra-operatively to avoid this prolonged effect. • Naloxone antagonizes (reverses) all opiates, but its effect quickly wears off. • Commonly available inexpensive opiates are pethidine and morphine. • Morphine has about ten times the potency and a longer duration of action than pethidine.
    [Show full text]
  • Pain Management in Patients with Substance-Use Disorders
    Pain Management in Patients with Substance-Use Disorders By Valerie Prince, Pharm.D., FAPhA, BCPS Reviewed by Beth A. Sproule, Pharm.D.; Jeffrey T. Sherer, Pharm.D., MPH, BCPS; and Patricia H. Powell, Pharm.D., BCPS Learning Objectives regarding drug interactions with illicit substances or prescribed pain medications. Finally, there are issues 1. Construct a therapeutic plan to overcome barri- ers to effective pain management in a patient with related to the comorbidities of the patient with addic- addiction. tion (e.g., psychiatric disorders or physical concerns 2. Distinguish high-risk patients from low-risk patients related to the addiction) that should influence product regarding use of opioids to manage pain. selection. 3. Design a treatment plan for the management of acute pain in a patient with addiction. Epidemiology 4. Design a pharmacotherapy plan for a patient with Pain is the second most common cause of work- coexisting addiction and chronic noncancer pain. place absenteeism. The prevalence of chronic pain may 5. Design a pain management plan that encompasses be much higher among patients with substance use dis- recommended nonpharmacologic components for orders than among the general population. In the 2006 a patient with a history of substance abuse. National Survey on Drug Use and Health, past-year alco- hol addiction or abuse occurred in 10.3% of men and 5.1% of women. In the same survey, 12.3% of men and Introduction 6.3% of women were reported as having a substance-use Pain, which is one of the most common reasons disorder (abuse or addiction) during the past year.
    [Show full text]
  • A Matter of Record (301) 890-4188 FOOD and DRUG
    1 1 FOOD AND DRUG ADMINISTRATION 2 CENTER FOR DRUG EVALUATION AND RESEARCH 3 4 5 JOINT MEETING OF THE ANESTHETIC AND ANALGESIC 6 DRUG PRODUCTS ADVISORY COMMITTEE (AADPAC) 7 AND THE DRUG SAFETY AND RISK MANAGEMENT 8 ADVISORY COMMITTEE (DSaRM) AND THE 9 PEDIATRIC ADVISORY COMMITTEE (PAC) 10 11 Friday, September 16, 2016 12 8:07 a.m. to 2:39 p.m. 13 14 15 FDA White Oak Campus 16 10903 New Hampshire Avenue 17 Building 31 Conference Center 18 The Great Room (Rm. 1503) 19 Silver Spring, Maryland 20 21 22 A Matter of Record (301) 890-4188 2 1 Meeting Roster 2 DESIGNATED FEDERAL OFFICER (Non-Voting) 3 Stephanie L. Begansky, PharmD 4 Division of Advisory Committee and Consultant 5 Management 6 Office of Executive Programs, CDER, FDA 7 8 ANESTHETIC AND ANALGESIC DRUG PRODUCTS ADVISORY 9 COMMITTEE MEMBERS (Voting) 10 Brian T. Bateman, MD, MSc 11 Associate Professor of Anesthesia 12 Division of Pharmacoepidemiology and 13 Pharmacoeconomics 14 Department of Medicine 15 Brigham and Women’s Hospital 16 Department of Anesthesia, Critical Care, and Pain 17 Medicine 18 Massachusetts General Hospital 19 Harvard Medical School 20 Boston, Massachusetts 21 22 A Matter of Record (301) 890-4188 3 1 Raeford E. Brown, Jr., MD, FAAP 2 (Chairperson) 3 Professor of Anesthesiology and Pediatrics 4 College of Medicine 5 University of Kentucky 6 Lexington, Kentucky 7 8 David S. Craig, PharmD 9 Clinical Pharmacy Specialist 10 Department of Pharmacy 11 H. Lee Moffitt Cancer Center & Research Institute 12 Tampa, Florida 13 14 Charles W. Emala, Sr., MS, MD 15 Professor and Vice-Chair for Research 16 Department of Anesthesiology 17 Columbia University College of Physicians & 18 Surgeons 19 New York, New York 20 21 22 A Matter of Record (301) 890-4188 4 1 Anita Gupta, DO, PharmD 2 (via telephone on day 1) 3 Vice Chair and Associate Professor 4 Division of Pain Medicine & Regional 5 Anesthesiology 6 Department of Anesthesiology 7 Drexel University College of Medicine 8 Philadelphia, Pennsylvania 9 10 Jennifer G.
    [Show full text]